Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8148401 | PFIZER | Benzimidazole derivatives |
Jan, 2031
(7 years from now) | |
US10414748 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8431597 | PFIZER | Benzimidazole derivatives |
Jun, 2028
(5 years from now) | |
US11168066 | PFIZER | Crystalline forms of 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate |
Apr, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 21, 2023 |
Orphan Drug Exclusivity (ODE) | Nov 21, 2025 |
NCE-1 date: 2022-11-21
Market Authorisation Date: 21 November, 2018
Treatment: Use, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (aml) in adult patients who are >= 75 years old or who have comorbidities that preclude use of...
Dosage: TABLET;ORAL
10
United States
4
Hungary
3
Poland
3
Canada
3
Slovenia
3
Korea, Republic of
3
Japan
3
Denmark
3
Argentina
3
Spain
3
Portugal
3
European Union
2
Brazil
2
Hong Kong
2
Taiwan
2
Lithuania
2
China
2
IB
2
New Zealand
2
Australia
2
South Africa
2
Israel
2
Peru
1
ME
1
Chile
1
Georgia
1
Dominican Republic
1
Cuba
1
Ukraine
1
Panama
1
Costa Rica
1
Morocco
1
RS
1
Netherlands
1
Honduras
1
Cyprus
1
Croatia
1
Guatemala
1
Malaysia
1
AP
1
Nicaragua
1
Uruguay
1
Mexico
1
EA
1
Colombia
1
Norway
1
Ecuador
1
Tunisia
1
Russia
1
Singapore
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic